Market Overview:
The global efavirenz/tenofovir/emtricitabine combination drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of HIV and rising demand for combination drugs. The global efavirenz/tenofovir/emtricitabine combination drug market is segmented on the basis of type, application, and region. On the basis of type, this market is segmented into 10 tables and 30 tables. The 10 tables segment is expected to grow at a higher CAGR than the 30 tables segment during the forecast period from 2018 to 2030. This can be attributed to factors such as lower cost and easy availability of 10 table combinations as compared with 30 table combinations. On the basis of application, this market is divided into hospital, clinic, drug center, and other segments. The hospital segment dominates this market owing to increased use of combination drugs for treatment purposes in hospitals across regions worldwide.
Product Definition:
Efavirenz/tenofovir/emtricitabine (Atripla) is a drug combination used to treat HIV infection. It is a fixed-dose tablet that contains efavirenz, tenofovir, and emtricitabine. Efavirenz/tenofovir/emtricitabine is used to prevent or delay the development of AIDS in people who have HIV infection.
10 Tables:
10 tables is the estimated number of patients that will be treated with efavirenz, tenofovir and emtricitabine in the first cycle of POC-HIV combination therapy. The product was developed by Gilead Sciences, Inc. as part of its HIV/AIDS drugs portfolio and was approved by FDA in June 2015 for treatment-naive patients.
30 Tables:
30 tables is the estimated number of tablets containing efavirenz, tenofovir and emtricitabine combination drug. The product was developed by Gilead Sciences, Inc. as a fixed-dose combination medication for the treatment of HIV-1 infection in adults and children who are 18 years or older.
Application Insights:
The other application segment includes the efavirenz/tenofovir/emtricitabine combination drug used in the treatment of HIV infection in children and adolescents. The use of tenofovir disoproxil fumarate is contraindicated in patients who are receiving antiretroviral therapy (ART) with a protease inhibitor or who are undergoing kidney dialysis.
Clinic-based settings accounted for a major share owing to extensive usage of efavirenz/tenofovir/emtricitabine combination drug as an alternative to zidovudine, lamivudine, and stavudine due to their better efficacy against HIV-1 infection. In addition, increasing prevalence of Aids has resulted in high demand for these drugs at low cost from clinics which is expected to drive market growth over the forecast period.
Regional Analysis:
North America dominated the global efavirenz/tenofovir/emtricitabine combination drug market in 2017. The presence of a large number of HIV patients, increasing awareness about the treatment options, and high healthcare expenditure are some factors attributing to its largest share. In addition, growing generic competition is expected to further drive growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to an increase in HIV cases coupled with a rise in government initiatives for mass medication programs against this disease. Moreover, improving access and penetration rates for expensive drugs such as efavirenz/tenofovir/emtricitabine combination tablets will boost revenue generation from 2016 to 2030 due to low cost compared with brand name products (USD X-13).
Growth Factors:
- Increasing incidence of HIV/AIDS: The global incidence of HIV is on the rise and is expected to reach 36 million by 2020. This will create a large pool of patients who will require treatment with antiretroviral drugs, such as efavirenz/tenofovir/emtricitabine combination drug.
- Rising awareness about HIV and its treatment: There is an increasing awareness among people about HIV and its treatment options. This will lead to an increase in the demand for efavirenz/tenofovir/emtricitabine combination drug in the coming years.
- Growing number of clinical studies on efavirenz/tenofovir/emtricitabine combination drug: A growing number of clinical studies are being conducted on efavirenz/tenofovir/emtricitabine combination drug, which is likely to boost its adoption in the near future.
- Availability of generic versions: Generic versions of efavirenz, tenofovir, and emtricitabine are available at a fractional cost as compared to their branded counterparts, making them more affordable for patients worldwide. This is likely to boost the adoption rate of this combo drug in developing countries in particular5
Scope Of The Report
Report Attributes
Report Details
Report Title
Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Research Report
By Type
10 Tables, 30 Tables
By Application
Hospital, Clinic, Drug Center, Other
By Companies
Gilead Sciences, Cipla, Emcure Pharmaceuticals, Mylan Pharmaceuticals, Sun Pharmaceutical Industries, Veritaz Healthcare, Alkem Laboratories
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
236
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Report Segments:
The global Efavirenz/Tenofovir/Emtricitabine Combination Drug market is segmented on the basis of:
Types
10 Tables, 30 Tables
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Drug Center, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Gilead Sciences
- Cipla
- Emcure Pharmaceuticals
- Mylan Pharmaceuticals
- Sun Pharmaceutical Industries
- Veritaz Healthcare
- Alkem Laboratories
Highlights of The Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 10 Tables
- 30 Tables
- By Application:
- Hospital
- Clinic
- Drug Center
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Efavirenz/Tenofovir/Emtricitabine Combination Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Efavirenz/Tenofovir/Emtricitabine is a combination drug used to treat HIV. It works by preventing the virus from multiplying and spreading in the body.
Some of the major companies in the efavirenz/tenofovir/emtricitabine combination drug market are Gilead Sciences, Cipla, Emcure Pharmaceuticals, Mylan Pharmaceuticals, Sun Pharmaceutical Industries, Veritaz Healthcare, Alkem Laboratories.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Efavirenz/Tenofovir/Emtricitabine Combination Drug Market - Supply Chain
4.5. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Forecast
4.5.1. Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Absolute $ Opportunity
5. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size and Volume Forecast by Type
5.3.1. 10 Tables
5.3.2. 30 Tables
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Drug Center
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Demand Share Forecast, 2019-2026
9. North America Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Drug Center
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size and Volume Forecast by Type
9.7.1. 10 Tables
9.7.2. 30 Tables
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Efavirenz/Tenofovir/Emtricitabine Combination Drug Demand Share Forecast, 2019-2026
10. Latin America Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Drug Center
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size and Volume Forecast by Type
10.7.1. 10 Tables
10.7.2. 30 Tables
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Efavirenz/Tenofovir/Emtricitabine Combination Drug Demand Share Forecast, 2019-2026
11. Europe Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Drug Center
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size and Volume Forecast by Type
11.7.1. 10 Tables
11.7.2. 30 Tables
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Efavirenz/Tenofovir/Emtricitabine Combination Drug Demand Share, 2019-2026
12. Asia Pacific Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Drug Center
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size and Volume Forecast by Type
12.7.1. 10 Tables
12.7.2. 30 Tables
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Efavirenz/Tenofovir/Emtricitabine Combination Drug Demand Share, 2019-2026
13. Middle East & Africa Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Drug Center
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Size and Volume Forecast by Type
13.7.1. 10 Tables
13.7.2. 30 Tables
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Efavirenz/Tenofovir/Emtricitabine Combination Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Efavirenz/Tenofovir/Emtricitabine Combination Drug Market: Market Share Analysis
14.2. Efavirenz/Tenofovir/Emtricitabine Combination Drug Distributors and Customers
14.3. Efavirenz/Tenofovir/Emtricitabine Combination Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Gilead Sciences
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Cipla
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Emcure Pharmaceuticals
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Mylan Pharmaceuticals
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Sun Pharmaceutical Industries
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Veritaz Healthcare
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Alkem Laboratories
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
